[关键词]
[摘要]
目的 建立UPLC法同时测定羊耳菊Inula cappa中7种化学成分(1,3-O-二咖啡酰基奎宁酸、1,5-O-二咖啡酰基奎宁酸、3,5-O-二咖啡酰基奎宁酸、4,5-O-二咖啡酰基奎宁酸、3-O-咖啡酰基奎宁酸、4-O-咖啡酰基奎宁酸、5-O-咖啡酰基奎宁酸)的方法,并基于该方法建立羊耳菊药材指纹图谱。方法 采用WATERS ACQUITY UPLC BEH C18色谱柱(100 mm×2.1 mm,1.7 μm),流动相为0.1%乙酸水溶液-乙腈,梯度洗脱,柱温为30 ℃,样品温度为4 ℃,体积流量为0.4 mL/min,检测波长为329 nm。结果 测定了广西、贵州、云南3个省份共20批羊耳菊样品中7种成分的量,建立了羊耳菊药材指纹图谱,共确定了20个共有峰,除样品18(S18)外,样品相似度均在0.900以上。以羊耳菊中7种成分的量及与对照指纹图谱的相似度进行单因素方差分析、聚类分析和主成分分析,结果显示,仅1,3-O-二咖啡酰基奎宁酸、1,5-O-二咖啡酰基奎宁酸的量在产地间有显著差异,20批样品被聚为2类,广西壮族自治区羊耳菊质量均一性较贵州、云南省高。结论 所建立的方法快速、准确,可用于羊耳菊的质量评价。
[Key word]
[Abstract]
Objective This study is aimed at developing an UPLC method for simultaneous determination of 1, 3-O-dicaffeoylquinic acid, 1,5-O-dicaffeoylquinic acid, 3,5-O-dicaffeoylquinic acid, 4,5-O-dicaffeoylquinic acid, 3-O-caffeoylquinic acid, 4-O-caffeoylquinic acid, and 5-O-caffeoylquinic acid and fingerprint analysis of Inula cappa. Methods WATERS ACQUITY UPLC BEH C18 column with gradient elution of 0.1% acetic acid-acetonitrile at a flow rate of 0.4 mL/min was employed for analysis of 20 batches of samples from three provinces or autonomous region. The detected wavelength was set at 329 nm. The column temperature was maintained at 30 ℃ and the sample solutions were maintained at 4 ℃ before analysis. Results Twenty peaks were selected as the common peaks in fingerprint and the similarity of samples was above 0.900 except S18. The variance analysis, hierarchical clustering analysis, and principle component analysis were employed for the quality evaluation based on the contents of seven components and fingerprint similarity. The results indicated that the contents of 1,3- and 1,5-O-dicaffeoylquinic acid were significantly different among three provinces or autonomous region. The clustering analysis results showed that 20 batches of samples were divided into two classes and the quality of samples from Guangxi provinves were more stable than those from Guizhou and Yunnan. Conclusion The established method could be rapid and accurate to evaluate the quality of I. cappa.
[中图分类号]
[基金项目]
国家"重大新药创制"科技重大专项(2013ZX09402202)